Kamada Ltd. share price today

Kamada Ltd.'s share price was $7.42 at the close on 4 November 2026. That is 7.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $7 and $9, and at that close it sat 35% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 12 weeks in a row.

Over the last 1 year the share price moved −4% while the S&P 500 moved +23%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Kamada Ltd. has 1 quarter of declared dividends on file, too few for a 12-month total. The most recent declaration was $0.25 for Dec 2025.

A dividend is cash paid out for each share. The 12-month total is the four most recent quarters added together.

Kamada Ltd. declared a dividend in 1 of the last 12 reported quarters, most recently $0.25 for Dec 2025. That is fewer than four quarters, so no 12-month total is shown.

Kamada Ltd. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Kamada Ltd. earned $9.3 M of net profit in the Jun 2026 quarter, +25.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $20.2 M. That is 16.9% of the quarter's revenue. The same quarter a year earlier earned $7.4 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $20.2 M (+39.7% on the year before).

Why profit moved: revenue changed +22.7% on a year earlier and the margin moved +1.5 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +15.1% and revenue +13.2%. Profit and revenue are moving at about the same pace.

Kamada Ltd. reported $54.9 M of revenue in the Jun 2026 quarter, +22.7% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 4 years it has grown 14.9% a year on average. The last full year, FY25, came in at $180 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $192 M.

FY25 revenue was $180 M, +12.1% on the year before.

Recent pace: the last four quarters grew +13.2% on average, against 14.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +13.2%, against +11.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +17.0%, against +21.5% a year (rolling over).

Kamada Ltd.'s operating margin was 17.3% in the Jun 2026 quarter, 1.5 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.1% and 14.5%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 1.1% and 14.5%, and FY25's 14.5% is the highest of them.

Why the margin moved: operating margin changed +1.5 percentage points on the year while gross margin changed −1.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 180% of Kamada Ltd.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $25.5 M of operating cash against $20.2 M of profit. After $9.8 M of spending on assets, $15.6 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Kamada Ltd. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $26.4 M on assets over the last 3 years. Averaged over those years that is 4.9% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $26.4 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Kamada Ltd.'s P/E is 20.6×, in the middle of its own history: higher than 41% of past readings. Its usual P/E (the middle reading) is 21.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved +40.0% while the price moved +11.4%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Kamada Ltd.'s business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +339.3% at its peak to +17.0%, but the business is still expanding, with ROCE steady at 8.5%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Kamada Ltd. earned a ROE of 8% in FY25. That is up from a low of −1% in FY21. Its return on capital used (ROIC) is 6.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 11.2% net margin and 0.48× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 11.2% net margin × 0.48× asset turnover × 1.41× leverage (assets divided by equity) ≈ 7.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 11.3% − 5.0% = +6.3 percentage points. The 5.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

Kamada Ltd. has total debt of $11.8 M against shareholder equity of $270 M as of Jun 2026, so its debt is 0.04× its equity, which is very little. Year by year, that ratio went from 0.14 in FY21 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for Kamada Ltd., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Kamada Ltd., the Z-score is 3.47. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 3.47 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Kamada Ltd. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Kamada Ltd. is the 42nd largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Aquestive Therapeutics, Inc., Alpha Teknova, Inc. and Tilray Brands, Inc. Just below it: Aurora Cannabis Inc., Canopy Growth Corporation and Emergent BioSolutions Inc.

Drug Manufacturers - Specialty & Generic companies close in size

39. Aquestive Therapeutics, Inc. $478 million
40. Alpha Teknova, Inc. $455 million
41. Tilray Brands, Inc. $434 million
42. Kamada Ltd. $408 million
43. Aurora Cannabis Inc. $344 million
44. Canopy Growth Corporation $318 million
45. Emergent BioSolutions Inc. $303 million

All 51 Drug Manufacturers - Specialty & Generic companies, largest first

Companies close in size in other industries

2975. Intrepid Potash, Inc. $407 million · Agricultural Inputs
2976. Assembly Biosciences, Inc. $406 million · Biotechnology
2977. Kamada Ltd. $405 million
2978. LendingTree, Inc. $405 million · Financial Conglomerates
2979. Verra Mobility Corporation $404 million · Information Technology Services

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.